ATE540971T1 - Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes - Google Patents

Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes

Info

Publication number
ATE540971T1
ATE540971T1 AT06745190T AT06745190T ATE540971T1 AT E540971 T1 ATE540971 T1 AT E540971T1 AT 06745190 T AT06745190 T AT 06745190T AT 06745190 T AT06745190 T AT 06745190T AT E540971 T1 ATE540971 T1 AT E540971T1
Authority
AT
Austria
Prior art keywords
diabetes
type
protein kinase
inhibitors
insulin resistance
Prior art date
Application number
AT06745190T
Other languages
English (en)
Inventor
Eleazar Shafrir
Ehud Ziv
Hadas Reuveni
Masha Niv
Original Assignee
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service filed Critical Hadasit Med Res Service
Application granted granted Critical
Publication of ATE540971T1 publication Critical patent/ATE540971T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT06745190T 2005-06-29 2006-06-28 Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes ATE540971T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69469105P 2005-06-29 2005-06-29
PCT/IL2006/000755 WO2007000770A2 (en) 2005-06-29 2006-06-28 Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes

Publications (1)

Publication Number Publication Date
ATE540971T1 true ATE540971T1 (de) 2012-01-15

Family

ID=37441619

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06745190T ATE540971T1 (de) 2005-06-29 2006-06-28 Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes

Country Status (6)

Country Link
US (1) US8575307B2 (de)
EP (1) EP1896496B1 (de)
JP (1) JP5143729B2 (de)
AT (1) ATE540971T1 (de)
AU (1) AU2006263332B2 (de)
WO (1) WO2007000770A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456700B (zh) 2014-01-29 2020-02-18 斯特拉斯堡大学 糖尿病治疗和预防的新靶标
EP3117831A1 (de) * 2015-07-16 2017-01-18 Nuritas Limited Peptide zur verwendung bei der förderung des glucosetransports in skelettmuskeln
DK3322430T3 (da) 2015-07-16 2020-06-29 Nuritas Ltd Antiinflammatoriske peptider, og anvendelser deraf
EP3118216A1 (de) 2015-07-16 2017-01-18 Nuritas Limited Zellwachstum und proliferation fördernde peptide und verwendungen davon
CA3050106A1 (en) * 2017-01-19 2018-07-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apoc-ii mimetic peptides
EP3421485A1 (de) 2017-06-30 2019-01-02 Université de Strasbourg Peptide zur behandlung und prävention von hyperglykämie
EP3897697B1 (de) * 2018-12-21 2023-03-29 Université de Strasbourg Peptide zur behandlung und prävention von diabetes und damit verbundenen erkrankungen
WO2023080790A1 (en) * 2021-11-02 2023-05-11 Tosoj As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923802A (en) * 1985-06-13 1990-05-08 Immunex Corporation Peptide substrates for the detection, characterization and purification of protein kinase C
US5783405A (en) * 1994-02-01 1998-07-21 Terrapin Technologies, Inc. Rapid screening method for effectors of signal transduction
US6511811B1 (en) * 1995-06-07 2003-01-28 The Regents Of The University Of California Protein kinase C antagonist related to insulin receptor
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
US6174993B1 (en) 1997-05-21 2001-01-16 The Children's Medical Center Corp. Short peptides which selectively modulate the activity of serine/threonine kinases
NZ508767A (en) 1998-07-06 2003-12-19 Robert O Use of inhibitors of protein kinase c epsilon to treat pain
US6376467B1 (en) 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
US6717030B2 (en) 1998-07-06 2004-04-06 The Regents Of The University Of California Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
CN1319133A (zh) 1998-09-25 2001-10-24 儿童医疗中心有限公司 选择性地调节蛋白激酶活性的短肽
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2002052033A1 (en) * 2000-12-22 2002-07-04 Joslin Diabetes Center, Inc. Pkc monocyte assay
US6881334B2 (en) * 2002-10-31 2005-04-19 Stanadyne Corporation Eccentric interference retention system for a filter cartridge
CA2539132A1 (en) 2003-09-16 2005-03-24 Garvan Institute Of Medical Research Methods for identifying modulators of protein kinase c-epsilon (pkc.epsilon.) and method of treatment of aberrant glucose metabolism associated therewith

Also Published As

Publication number Publication date
JP5143729B2 (ja) 2013-02-13
US20100216701A1 (en) 2010-08-26
JP2008544980A (ja) 2008-12-11
EP1896496B1 (de) 2012-01-11
WO2007000770A2 (en) 2007-01-04
AU2006263332A1 (en) 2007-01-04
AU2006263332B2 (en) 2012-02-23
US8575307B2 (en) 2013-11-05
EP1896496A2 (de) 2008-03-12
WO2007000770A3 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
FR23C1024I1 (fr) Composition stable d'une protéine anabolique osseuse qui est un analogue de pthrp, et ses emplois
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EA200702656A1 (ru) Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение
EA200601553A1 (ru) Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
EP2537524A3 (de) Behandlung von T-Zell-vermittelten Krankheiten
WO2008080082A3 (en) Methods for modulating set and uses thereof
MX2009007008A (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
IL172783A0 (en) Rasgap derived peptide for selectively killing cancer cells
ATE427116T1 (de) Behandlung von bakteriellen infektionen
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
WO2007016228A3 (en) 5-substituted thiazol-2-yl amino compounds and compositions as protein kinase inhibitors
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
DE602006015837D1 (de) Formulierungen von tipifarnib zur intravenösen verabreichung
WO2005002500A3 (en) Inhibitors of coronavirus
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
ATE469168T1 (de) Peptide zur transglutaminase-hemmung
WO2005070445A3 (en) Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
EP4088731A4 (de) Zusammensetzung mit peptid oder peptidverbindung als wirkstoff und deren medizinische verwendung